Libura, M., Bialopiotrowicz, E., Giebel, S., Wierzbowska, A., Roboz, G. J., Piatkowska-Jakubas, B., . . . Haus, O. (2021). IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen. Nature Portfolio.
Chicago Style (17th ed.) CitationLibura, Marta, et al. IDH2 Mutations in Patients with Normal Karyotype AML Predict Favorable Responses to Daunorubicin, Cytarabine and Cladribine Regimen. Nature Portfolio, 2021.
MLA (8th ed.) CitationLibura, Marta, et al. IDH2 Mutations in Patients with Normal Karyotype AML Predict Favorable Responses to Daunorubicin, Cytarabine and Cladribine Regimen. Nature Portfolio, 2021.
Warning: These citations may not always be 100% accurate.